Core Insights - The potential of oncolytic virus therapy to shrink tumors, reactivate the immune system, and extend the lives of late-stage cancer patients is highlighted, with ongoing clinical trials in China showing promise [1][2]. Group 1: Oncolytic Virus Therapy Overview - Oncolytic viruses are engineered to infiltrate tumors, replicate within cancer cells, and trigger their destruction while also training the immune system to target remaining cancer cells [2]. - Five oncolytic virus therapies have been approved globally, primarily in the US and Japan, with China making rapid advancements in this field [2]. Group 2: Encouraging Results - A case study published in *Cell* reported that a 58-year-old woman with late-stage cervical cancer experienced complete tumor disappearance and survived for over 36 months after receiving experimental oncolytic virus therapy [3]. - A small trial led by Professor Zhao Yongxiang found that 90% of patients with drug-resistant cancers (liver, ovarian, and lung cancers) showed tumor reduction or stabilization after treatment with a genetically modified virus [3]. - Another team in Zhejiang developed VG161, which inhibited 65% of liver tumor growth and extended the average life expectancy of late-stage cancer patients from 9.4 months to 17.3 months with minimal side effects [3]. Group 3: Cost-Effectiveness - Oncolytic virus therapy is significantly cheaper than CAR-T therapy, costing only $140 per injection compared to approximately $140,000 for CAR-T, making annual treatment costs below $4,200 [6]. Group 4: Challenges and Future Outlook - Despite the promising results, challenges remain, such as the need for multiple injections and potential mild flu-like symptoms due to the live viruses [7]. - Experts remain optimistic about the transformative potential of this therapy, considering it the next frontier in oncology [7].